Anika Therapeutics, Inc. (ANIK) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — ANIK

Balance Sheet

(in millions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	38.41	41.02	57.99	53.17	53.37	62.37	62.82	68.63	70.65	65.07	79.74	87.78	91.39	90.33	90.98	97.18	94.60
Short-term Investments	--	25.77	22.19	23.96	21.99	28.36	33.77	32.08	34.68	36.74	30.63	34.17	32.17	29.31	--	0.00	0.00
Accounts Receivable	29.06	25.77	22.19	23.96	21.99	28.36	33.77	32.08	34.68	36.74	30.63	--	--	--	32.35	29.43	26.51
Inventory	28.57	22.84	16.28	16.92	21.34	39.63	51.46	49.41	43.72	42.60	41.32	37.24	35.34	35.23	35.02	42.86	42.72
Total Current Assets	99.19	93.56	101.59	99.32	102.51	136.11	155.00	158.96	156.78	152.20	160.33	167.76	167.86	165.32	165.78	177.76	173.47
Property, Plant & Equipment	40.10	39.72	40.68	41.08	40.46	44.57	47.69	46.06	45.94	47.99	48.80	47.39	48.09	47.95	49.11	49.54	49.13
Goodwill	7.83	7.89	8.05	8.06	7.42	7.66	7.35	7.40	7.25	7.47	7.46	6.72	7.17	7.63	7.95	8.15	8.05
Intangible Assets	1.65	1.65	1.65	0.01	0.63	1.43	2.32	2.65	68.76	70.71	72.65	76.55	78.49	80.44	85.02	87.08	88.99
Total Non-current Assets*	84.28	85.83	87.85	88.37	88.10	95.30	107.66	104.78	171.38	176.68	178.74	179.99	186.27	176.92	187.15	185.37	188.78
Total Assets	183.47	179.39	189.44	187.68	190.61	231.41	262.65	263.74	328.16	328.88	339.07	347.75	354.12	342.24	352.93	363.13	362.25
Accounts Payable	6.24	6.34	4.73	4.77	5.28	6.81	9.99	10.02	8.25	7.94	8.95	8.35	8.16	7.44	7.94	8.10	8.68
Total Current Liabilities	22.15	20.97	19.09	16.08	17.90	25.49	26.12	28.46	28.06	23.46	28.69	26.35	29.43	26.99	28.77	41.37	46.97
Total Non-current Liabilities*	24.05	24.52	23.54	23.93	24.31	26.05	26.20	26.75	29.61	31.41	32.79	36.46	38.54	29.46	34.10	34.96	38.62
Total Liabilities*	46.19	45.49	42.63	40.01	42.21	51.54	52.32	55.21	57.67	54.87	61.49	62.81	67.97	56.45	62.87	76.33	85.60
Retained Earnings	59.04	55.73	60.50	62.82	66.79	93.53	123.45	123.54	191.05	197.63	200.37	215.63	219.80	222.65	231.37	230.81	224.28
Total Stockholder Equity	137.28	133.90	146.81	147.67	148.40	179.86	210.34	208.54	270.49	274.02	277.59	284.94	286.15	285.79	290.06	286.80	276.66

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Total Revenue	32.61	29.61	30.62	27.82	28.22	26.17	(1.29)	38.75	41.92	40.52	42.97	41.47	44.30	37.92	39.62	40.26	39.66	36.69	35.82	39.54
Cost of Revenue	11.37	10.62	11.44	12.23	13.86	11.49	(23.85)	37.31	14.56	15.90	16.64	16.52	15.33	15.08	15.49	17.49	14.80	14.89	17.69	16.51
Gross Profit	21.24	19.00	19.18	15.58	14.36	14.68	22.57	1.44	27.37	24.63	26.33	24.94	28.97	22.84	24.13	22.78	24.86	21.80	18.13	23.02
Research & Development	7.34	6.71	6.45	6.95	6.31	6.06	2.74	7.24	7.40	8.16	7.59	7.79	8.91	8.40	7.75	7.30	6.98	6.16	6.00	7.67
Selling, General & Admin	10.95	17.77	12.08	11.87	12.23	12.91	(4.89)	19.11	19.81	21.53	20.34	24.83	23.69	27.00	23.05	21.28	21.27	19.20	20.43	17.50
Total Operating Expenses	18.29	24.49	18.53	18.82	18.54	18.97	(5.25)	29.46	27.20	29.69	90.11	100.62	32.60	35.40	30.80	28.58	28.24	25.36	27.26	21.72
Operating Income	2.95	(5.49)	0.65	(3.23)	(4.18)	(4.28)	27.82	(28.02)	0.16	(5.06)	(63.78)	(7.67)	(3.63)	(12.55)	(6.67)	(5.80)	(3.38)	(3.55)	(9.12)	1.30
Pretax Income	3.38	(4.82)	0.76	(2.24)	(3.97)	(3.87)	28.56	(27.61)	0.76	(4.47)	(63.20)	(7.04)	(3.07)	(12.01)	(6.39)	(5.36)	(3.28)	(3.71)	(9.17)	1.25
Tax Provision	0.07	0.24	(1.04)	0.94	0.68	0.09	2.87	2.31	0.84	0.04	(0.20)	(0.46)	(0.33)	(1.66)	(1.48)	(1.19)	(0.44)	(0.77)	(3.38)	0.69
Net Income	3.31	(5.06)	0.29	(2.33)	(3.97)	(4.87)	(21.86)	(29.92)	(0.09)	(4.51)	(63.00)	(6.58)	(2.74)	(10.35)	(4.91)	(4.17)	(2.84)	(2.93)	(5.79)	0.56
Basic EPS	0.25	(0.37)	0.02	(0.16)	(0.28)	(0.34)	(1.48)	(2.03)	(0.01)	(0.31)	(4.29)	(0.45)	(0.19)	(0.71)	(0.33)	(0.29)	(0.20)	(0.20)	(0.40)	0.04
Diluted EPS	0.24	(0.37)	0.02	(0.16)	(0.28)	(0.34)	(1.48)	(2.03)	(0.01)	(0.31)	(4.29)	(0.45)	(0.19)	(0.71)	(0.33)	(0.29)	(0.20)	(0.20)	(0.41)	0.04

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Operating Cash Flow	(0.68)	(4.85)	4.64	6.87	(0.19)	(0.13)	1.58	5.02	(1.07)	(0.13)	3.64	6.49	(8.29)	(3.62)	0.48	2.71	3.09	(1.87)	4.47	2.06
Capital Expenditures	1.45	1.43	0.65	1.89	1.47	2.82	1.31	1.22	3.40	1.81	1.84	0.74	1.46	1.39	2.53	1.69	1.94	1.33	1.13	1.28
Free Cash Flow*	(2.13)	(6.28)	3.99	4.98	(1.66)	(2.95)	0.28	3.80	(4.47)	(1.93)	1.80	5.74	(9.75)	(5.01)	(2.05)	1.02	1.15	(3.19)	3.35	0.78
Investing Cash Flow	(1.28)	(1.24)	0.20	(1.73)	(0.54)	1.67	(1.31)	(1.82)	(3.40)	(1.81)	(1.84)	(0.74)	(1.46)	(1.39)	(2.53)	(1.69)	(1.94)	(1.33)	(1.24)	(1.29)
Financing Cash Flow	(0.70)	(10.35)	(5.28)	(0.01)	0.18	(5.44)	(5.35)	(3.99)	(1.11)	(2.27)	0.34	(0.11)	(4.94)	(1.61)	0.67	(4.61)	(0.05)	(0.86)	0.06	(6.98)

* Derived from reported values